Cynata Therapeutics Limited has advanced its corporate governance and risk management practices, including the adoption of a Diversity Policy and a robust risk management framework. The company’s Board has adopted a Diversity Policy, which provides a framework for the company to establish and achieve measurable diversity objectives, including gender, age, ethnicity, and cultural diversity. However, due to the company’s current size and level of operations, the Board has not yet set measurable objectives for achieving gender diversity.
Material actions and disclosures
The Board conducts an annual review of its structure, composition, and performance, assessing the Board’s performance over the previous 12 months in relation to corporate strategies, operating plans, and the annual budget. The company also has a Communication Strategy that facilitates shareholder participation at meetings and encourages the use of electronic communications to enhance transparency and accessibility.
The company has implemented a Code of Conduct aimed at maintaining high ethical standards, corporate behaviour, and accountability within the organisation. Additionally, a Whistleblower Protection Policy and an Anti-Bribery and Corruption Policy have been adopted, both of which are available on the company’s website.
Forward commitments
The Board is committed to the ongoing development of a strategic and consistent enterprise-wide risk management program, underpinned by a risk-conscious culture. The company does not have a separate Risk Committee but the Board carries out the duties that would ordinarily be carried out by the Risk Committee under the Audit, Risk and Compliance Policy.
The Board reviews the company’s risk management framework at each scheduled Board meeting to ensure it continues to effectively manage risk.
Cynata Therapeutics Limited’s Corporate Governance Charters, Policies, and Procedures are available on the company’s website at https://www.cynata.com/corporate-governance.
Attributed to the Corporate Governance Statement of Cynata Therapeutics Limited.